Jambi Ebtihaj J, Abdulaziz Alshubaily Fawzia
Department of Biochemistry, Faculty of Science, King Abdulaziz University, P.O. Box 42695, Jeddah 21551, Saudi Arabia.
King Fahad Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia.
Saudi J Biol Sci. 2022 Sep;29(9):103393. doi: 10.1016/j.sjbs.2022.103393. Epub 2022 Jul 25.
Osteosarcoma is a primary malignant cancer of the bone identified by the direct formation of osteoid tissue or immature bone by cancer cells. The liver and kidneys represent two major secondary organs to which osteosarcoma metastasizes. In this study, we assessed Shilajit, a phytomineral diffusion traditionally used in Ayurvedic medicine, for its possible protective effects against metastasis induced liver and kidney damages in an osteosarcoma rat model. Osteosarcoma rats displayed typical dysregulation of serum levels of hepatic and renal functional markers (p < 0.05) including aspartate aminotransferase (AST)* and alanine aminotransferase (ALT), alkaline phosphatase (ALP), total proteins, albumin, bilirubin, creatinine, urea, and uric acid. Changes in functional markers were also positively correlated with marked histopathological alterations in liver and kidney tissues. Whereas Shilajit's treatment of osteosarcoma rates in combination with CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) chemotherapy drug cocktail significantly (p < 0.05) reversed the studied functional markers to their near-normal levels. Co-treatment of shilajit and drug cocktails also markedly alleviated histopathological changes in liver and kidney tissues. Correlation co-efficient analysis of hepatic and renal functional markers revealed a significant inter-association among these markers. Collectively, present data indicate that shilajit may potentiate the effects of chemotherapy drugs and mitigate the metastasis-induced liver and kidney damage in osteosarcoma. Thus, the findings of this study substantiate the beneficial health effects of shilajit and promote its regular consumption.
骨肉瘤是一种原发性骨恶性肿瘤，其特征是癌细胞直接形成类骨质组织或不成熟骨。肝脏和肾脏是骨肉瘤转移的两个主要继发器官。在本研究中，我们评估了希拉季特（一种传统上用于阿育吠陀医学的植物矿物质提取物）对骨肉瘤大鼠模型中转移诱导的肝损伤和肾损伤的可能保护作用。骨肉瘤大鼠表现出肝肾功能标志物血清水平的典型失调（p < 0.05），包括天冬氨酸转氨酶（AST）*、丙氨酸转氨酶（ALT）、碱性磷酸酶（ALP）、总蛋白、白蛋白、胆红素、肌酐、尿素和尿酸。功能标志物的变化也与肝和肾组织中明显的组织病理学改变呈正相关。而希拉季特与CMF（环磷酰胺、甲氨蝶呤和5-氟尿嘧啶）化疗药物鸡尾酒联合治疗骨肉瘤大鼠，显著（p < 0.05）使所研究的功能标志物恢复到接近正常水平。希拉季特与药物鸡尾酒联合治疗也显著减轻了肝和肾组织的组织病理学变化。肝肾功能标志物的相关系数分析显示这些标志物之间存在显著的相互关联。总体而言，目前的数据表明希拉季特可能增强化疗药物的作用，并减轻骨肉瘤转移诱导的肝和肾损伤。因此，本研究结果证实了希拉季特对健康有益，并提倡经常食用。
